drugset
drugset / Trial / NCT04102202

BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus

NCT04102202 ↗

Phase 1/2 Withdrawn Breath of Life International Pharma Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM)

Timeline

Start
2020-11-15
Primary completion
2021-03-22
Completion
2021-03-22

Outcome

Outcome not reported

Stopped (Business): “Due to company strategic decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject BOL-DP-o-05 Unknown — —

Indications

type 1 diabetes mellitus